Do Benefits Outweigh Risks for Corticosteroid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in People with Diabetes Mellitus?

References

• World Health Organisation. COPD factsheet. Fact Sheets; 2017 Available from: http://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed 17, 2019.
   Google Scholar
• CavaillèsA, Brinchault-rabinG, DixmierA, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22:454–475. doi:10.1183/09059180.0000861224293462
   PubMedGoogle Scholar
• ChatilaWM, ThomashowBM, MinaiOA, CrinerGJ, MakeBJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549–555. doi:10.1513/pats.200709-148ET18453370
   PubMedGoogle Scholar
• McAuleySA, HorsburghJC, WardGM, et al. Insulin pump basal adjustment for exercise in type 1 diabetes: a randomised crossover study. Diabetologia. 2016;59:1636–1644. doi:10.1007/s00125-016-3981-927168135
   PubMed Web of Science ®Google Scholar
• VanfleterenLEGW. Does COPD stand for “COmorbidity with Pulmonary Disease”? Eur Respir J. 2015;45(1):14LP- 17. doi:10.1183/09031936.0014801425552731
   PubMed Web of Science ®Google Scholar
• ShinJA, LeeJH, LimSY, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013;4:334–343. doi:10.1111/jdi.12075
   PubMed Web of Science ®Google Scholar
• SattarN, GawA, ScherbakovaO, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419. doi:10.1161/01.CIR.0000080897.52664.9412860911
   PubMed Web of Science ®Google Scholar
• KengneAP, LimenSN, SobngwiE, DjouogoCFT, NouedouiC. Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan Africans. Diabetol Metab Syndr. 2012;4. doi:10.1186/1758-5996-4-22.
   PubMed Web of Science ®Google Scholar
• Garcia Lira NetoJC, de Almeida XavierM, JwpB, et al. Prevalence of metabolic syndrome in individuals with type 2 diabetes mellitus. Rev Bras Enferm. 2017;70(2):0145. doi:10.1590/0034-7167-2016-0145
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas Eighth Edition 2017; 2017. doi:10.1016/j.diabres.2009.10.007
   Google Scholar
• SaklayenMG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20. doi:10.1007/s11906-018-0812-z.
   PubMed Web of Science ®Google Scholar
• FathallahN, SlimR, LarifS, HmoudaH, Ben SalemC. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf. 2015;38:1153–1168. doi:10.1007/s40264-015-0339-z26370106
   PubMed Web of Science ®Google Scholar
• HolmanRR, PaulSK, BethelMA, MatthewsDR, NeilHA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589. doi:10.1056/NEJMoa080647018784090
   PubMed Web of Science ®Google Scholar
• ClarkePM, GrayAM, BriggsA, et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–1759. doi:10.1007/s00125-004-1527-z15517152
   PubMed Web of Science ®Google Scholar
• DCCT Study Group. Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care. 1990;13(4):427–433. doi:10.2337/diacare.13.4.4272180661
   PubMed Web of Science ®Google Scholar
• Gubitosi-klugRA, LachinJM, BacklundJYC, LorenziGM, BrillonDJ, OrchardTJ. Intensive diabetes treatment and cardiovascular outcomes in type1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016;39(5):686–693. doi:10.2337/dc15-199026861924
   PubMed Web of Science ®Google Scholar
• KingP, PeacockI, DonnellyR. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643–648. doi:10.1046/j.1365-2125.1999.00092.x10594464
   PubMed Web of Science ®Google Scholar
• GläserS, KrügerS, MerkelM, BramlageP, HerthFJF. Chronic obstructive pulmonary disease and diabetes mellitus: a systematic review of the literature. Respiration. 2015;89(3):253–264. doi:10.1159/00036986325677307
   PubMed Web of Science ®Google Scholar
• KerrEA, HeislerM, KreinSL, et al. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients’ treatment priorities and self-management? J Gen Intern Med. 2007;22(12):1635–1640. doi:10.1007/s11606-007-0313-217647065
   PubMed Web of Science ®Google Scholar
• CaugheyGE, PreissAK, VitryAI, GilbertAL, RougheadEE. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care. 2013;36(10):3009–3014. doi:10.2337/dc12-219723735725
   PubMed Web of Science ®Google Scholar
• Malte RasmussenS, BrokJ, BackerV, Francis ThomsenS, MeteranH. Association between chronic obstructive pulmonary disease and type 2 diabetes: a systematic review and meta-analysis. COPD J Chronic Obstr Pulm Dis. 2018;15:526–535. doi:10.1080/15412555.2018.1532495
   PubMed Web of Science ®Google Scholar
• ManninoDM, ThornD, SwensenA, HolguinF. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–969. doi:10.1183/09031936.0001240818579551
   PubMed Web of Science ®Google Scholar
• Cebron LipovecN, BeijersRJHCG, van den BorstB, DoehnerW, LainscakM, ScholsAMWJ. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. COPD J Chronic Obstr Pulm Dis. 2016;13:399–406. doi:10.3109/15412555.2016.1140732
   PubMed Web of Science ®Google Scholar
• AramburuA, ArosteguiI, MorazaJ, et al. COPD classification models and mortality prediction capacity. Int J COPD. 2019;14:605–613. doi:10.2147/COPD.S184695
   Google Scholar
• PikoulaM, QuintJK, NissenF, HemingwayH, SmeethL, DenaxasS. Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records. BMC Med Inform Decis Mak. 2019;19. doi:10.1186/s12911-019-0805-0.
   PubMed Web of Science ®Google Scholar
• HuangJ, ZengT, TianY, et al. Clinical significance of high‐mobility group box‐1 (HMGB1) in subjects with type 2 diabetes mellitus (T2DM) combined with chronic obstructive pulmonary disease (COPD). J Clin Lab Anal. 2019;33. doi:10.1002/jcla.22910
   Web of Science ®Google Scholar
• Amarante-mendesGP, AdjemianS, BrancoLM, ZanettiLC, WeinlichR, BortoluciKR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.02379.
   PubMed Web of Science ®Google Scholar
• BoltonCE, EvansM, IonescuAA, et al. Insulin resistance and inflammation - A further systemic complication of COPD. COPD J Chronic Obstr Pulm Dis. 2007;4:121–126. doi:10.1080/15412550701341053
   Google Scholar
• ParkSK, LarsonJL. The relationship between physical activity and metabolic syndrome in people with chronic obstructive pulmonary disease. J Cardiovasc Nurs. 2014;29:499–507. doi:10.1097/JCN.000000000000009624165700
   PubMed Web of Science ®Google Scholar
• GullifordMC, CharltonJ, LatinovicR. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728–2729. doi:10.2337/dc06-149917130214
   PubMed Web of Science ®Google Scholar
• van SandwijkMS, BemelmanFJ, Ten BergeIJM. Immunosuppressive drugs after solid organ transplantation. Neth J Med. 2013;71(6):281–289.23956308
   PubMed Web of Science ®Google Scholar
• QuellmannS, SchwarzerG, HübelK, GrebA, EngertA, BohliusJ. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation. Cochrane Database Syst Rev. 2008. doi:10.1002/14651858.CD004885.pub2
   PubMed Web of Science ®Google Scholar
• WaltersJAE, TanDJ, WhiteCJ, Wood-BakerR. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018. doi:10.1002/14651858.CD006897.pub4
   Web of Science ®Google Scholar
• StolzD, Christ-grainM, BingisserR, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19. doi:10.1378/chest.06-150017218551
   PubMed Web of Science ®Google Scholar
• HwangJ, WeissRE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014. doi:10.1002/dmrr
   PubMed Web of Science ®Google Scholar
• VestergaardP, RejnmarkL, MosekildeL. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest. 2007;132:1599–1607. doi:10.1378/chest.07-109217890464
   PubMed Web of Science ®Google Scholar
• HenzenC, SuterA, LerchE, UrbinelliR, SchornoXH, BrinerVA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000. doi:10.1016/S0140-6736(99)06290-X
   PubMed Web of Science ®Google Scholar
• GurwitzJH, BohnRL, GlynnRJ, MonaneM, MogunH, AvornJ. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97. doi:10.1001/archinte.154.1.978267494
   PubMedGoogle Scholar
• PlatL, ByrneMM, SturisJ, et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol Metab. 2017. doi:10.1152/ajpendo.1996.270.1.e36
   Web of Science ®Google Scholar
• WiseJK, HendlerR, FeligP. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest. 1973;52:2774–2782. doi:10.1172/JCI1074734748510
   PubMed Web of Science ®Google Scholar
• Van RaalteDH, OuwensDM, DiamantM. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest. 2009;39:81–93. doi:10.1111/j.1365-2362.2008.02067.x19200161
   PubMed Web of Science ®Google Scholar
• CadoudalT, LeroyerS, ReisAF, et al. Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome. Biochimie. 2005;87:27–32. doi:10.1016/j.biochi.2004.12.00515733733
   PubMed Web of Science ®Google Scholar
• Franckhauser-vogelS, Antras-ferryJ, RobinD, RobinP, ForestC. Transcriptional and posttranscriptional mechanisms of glucocorticoid- mediated repression of phosphoenolpyruvate carboxykinase gene expression in adipocytes. J Cell Biochem. 1997;66:386–393. doi:10.1002/(SICI)1097-4644(19970901)66:3<386::AID-JCB10>3.0.CO;2-D9257194
   PubMed Web of Science ®Google Scholar
• Van RaalteDH, NofrateV, BunckMC, et al. Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men. Eur J Endocrinol. 2010;162:729–735. doi:10.1530/EJE-09-103420124412
   PubMed Web of Science ®Google Scholar
• Van RaalteDH, BrandsM, Van Der ZijlNJ, et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia. 2011;54:2103–2112. doi:10.1007/s00125-011-2174-921562755
   PubMed Web of Science ®Google Scholar
• ÇaǧdaşDN, PaçFA, ÇakalE. Glucocorticoid-induced diabetic ketoacidosis in acute rheumatic fever. J Cardiovasc Pharmacol Ther. 2008;13:298–300. doi:10.1177/107424840832660919087951
   PubMed Web of Science ®Google Scholar
• HwangK, SmithJF, CowardRM, et al. Evaluation of the azoospermic male: a committee opinion. Fertil Steril. 2018;109(5):777–782. doi:10.1016/j.fertnstert.2018.01.04329778371
   PubMed Web of Science ®Google Scholar
• LinCS, LiuCC, YehCC, et al. Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: two nationwide population-based retrospective cohort studies. PLoS One. 2017. doi:10.1371/journal.pone.0181815
   Web of Science ®Google Scholar
• SuissaS, KezouhA, ErnstP. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001–1006. doi:10.1016/j.amjmed.2010.06.01920870201
   PubMed Web of Science ®Google Scholar
• PriceDB, RussellR, MaresR, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PLoS One. 2016;11:e0162903. doi:10.1371/journal.pone.016290327658209
   PubMed Web of Science ®Google Scholar
• NiewoehnerDE, ErblandML, DeupreeRH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340:1941–1947. doi:10.1056/NEJM19990624340250210379017
   PubMed Web of Science ®Google Scholar
• ShahS, SonawaneP, VaidyaS, SalviS, NaharP. Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India. 2013;30:108. doi:10.4103/0970-2113.11041723741090
   PubMedGoogle Scholar
• LitonjuaAA, LazarusR, SparrowD, DeMollesD, WeissST. Lung function in type 2 diabetes: the Normative Aging Study. Respir Med. 2005;99:1583–1590. doi:10.1016/j.rmed.2005.03.02316291079
   PubMed Web of Science ®Google Scholar
• AparnaA. Pulmonary function tests in type 2 diabetics and non-diabetic people - A comparative study. J Clin Diagnostic Res. 2013. doi:10.7860/JCDR/2013/6182.3237
   PubMedGoogle Scholar
• LangeP, GrothS, MortensenJ, et al. Diabetes mellitus and ventilatory capacity: a five year follow-up study. Eur Respir J. 1990;3(3):288–292.2340886
   PubMed Web of Science ®Google Scholar
• LimSY, RheeEJ, SungKC. Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in korean nonsmoking males. J Korean Med Sci. 2010;25:1480. doi:10.3346/jkms.2010.25.10.148020890430
   PubMed Web of Science ®Google Scholar
• KinneyGL, Black-shinnJL, WanES, et al. Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease. Diabetes Care. 2014;37:389–395. doi:10.2337/dc13-143524026562
   PubMed Web of Science ®Google Scholar
• MillerJ, EdwardsLD, AgustíA, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107:1376–1384. doi:10.1016/j.rmed.2013.05.00123791463
   PubMed Web of Science ®Google Scholar
• GeerlingsSE, HoepelmanAIM. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26:259–265. doi:10.1016/S0928-8244(99)00142-X10575137
   PubMed Web of Science ®Google Scholar
• AlvesC, CasqueiroJ, CasqueiroJ. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16:27. doi:10.4103/2230-8210.94253
   Google Scholar
• GanYH. Host susceptibility factors to bacterial infections in type 2 diabetes. PLoS Pathog. 2013;9:e1003794. doi:10.1371/journal.ppat.100379424385898
   PubMed Web of Science ®Google Scholar
• YehHC, PunjabiNM, WangNY, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes. Diabetes Care. 2008;31:741–746. doi:10.2337/dc07-146418056886
   PubMed Web of Science ®Google Scholar
• JuniorLA, KretzmannNA, TieppoJ, PicadaJN, DiasAS, MarroniNA. Lung alterations in a rat model of diabetes mellitus: effects of antioxidant therapy. J Bras Pneumol. 2010. doi:10.1590/S1806-37132010000500009[pii]
   Web of Science ®Google Scholar
• GillSK, HuiK, FarneH, et al. Increased airway glucose increases airway bacterial load in hyperglycaemia. Sci Rep. 2016;6. doi:10.1038/srep27636
   Web of Science ®Google Scholar
• MalliaP, WebberJ, GillSK, et al. Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;142:815–823.e6. doi:10.1016/j.jaci.2017.10.01729310905
   PubMed Web of Science ®Google Scholar
• MorettiM, CilioneC, MarchioniA, TampieriA, FracchiaC, NavaS. Incidence and causes of non-invasive mechanical ventilation failure after initial success. Thorax. 2000;55:819–825. doi:10.1136/thorax.55.10.81910992532
   PubMed Web of Science ®Google Scholar
• LoukidesS, PolyzogopoulosD. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration. 1996;63:170–173. doi:10.1159/0001965398739488
   PubMed Web of Science ®Google Scholar
• WaltersJAE, TanDJ, WhiteCJ, GibsonPG, Wood-BakerR, WaltersEH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:CD001288. doi:10.1002/14651858.CD001288.pub4
   Web of Science ®Google Scholar
• DaviesL, AngusRM, CalverleyPMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354:456–460. doi:10.1016/S0140-6736(98)11326-010465169
   PubMed Web of Science ®Google Scholar
• WaltersJA, WangW, MorleyC, SoltaniA, Wood-BakerR. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Syst Rev. 2011. doi:10.1002/14651858.cd006897.pub2
   Web of Science ®Google Scholar
• WoutersEF. Management of severe COPD. Lancet. 2004;364:883–895. doi:10.1016/S0140-6736(04)16984-515351196
   PubMed Web of Science ®Google Scholar
• LeuppiJD, SchuetzP, BingisserR, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. J Am Med Assoc. 2013;309:2223. doi:10.1001/jama.2013.5023
   PubMed Web of Science ®Google Scholar
• WaltersJAE, WaltersEH, Wood-bakerR. Oral corticosteroids for stable chronic obstructive pulmonary disease [Systematic Review]. Cochrane Database Syst Rev. 2005. doi:10.1002/14651858.CD005374
   Web of Science ®Google Scholar
• DecramerM, De BockV, DomR. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:1958–1964. doi:10.1164/ajrccm.153.6.86650618665061
   PubMed Web of Science ®Google Scholar
• McEvoyCE, EnsrudKE, BenderE, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:704–709. doi:10.1164/ajrccm.157.3.97030809517579
   PubMed Web of Science ®Google Scholar
• HoritaN, MiyazawaN, MoritaS, et al. Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease. Respir Res. 2014;15:37. doi:10.1186/1465-9921-15-3724708443
   PubMed Web of Science ®Google Scholar
• SinghD, AgustiA, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-201930846476
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• WedzichaJA, MiravitllesM, HurstJR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017. doi:10.1183/13993003.00791-2016
   Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Chronic Obstructive Pulmonary Disease Updated 2010 Global Initiative for Chronic Obstructive Lung Disease; 2016. doi:10.1097/00008483-200207000-00004
   Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2019 Available from: https://www.nice.org.uk/guidance/NG115. Accessed 33, 2020.
   Google Scholar
• LaueJ, ReierthE, MelbyeH. When should acute exacerbations of COPD be treated with systemic corticosteroids and antibiotics in primary care: a systematic review of current COPD guidelines. Npj Prim Care Respir Med. 2015. doi:10.1038/npjpcrm.2015.2
   PubMed Web of Science ®Google Scholar
• CevikerY, SayinerA. Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Pulm Pharmacol Ther. 2014;27:179–183. doi:10.1016/j.pupt.2013.03.00423518215
   PubMed Web of Science ®Google Scholar
• AaronSD, VandemheenKL, HebertP, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618–2625. doi:10.1056/nejmoa02316112826636
   PubMed Web of Science ®Google Scholar
• AlíaI, De La CalMA, EstebanA, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med. 2011;171:1939. doi:10.1001/archinternmed.2011.53022123804
   PubMed Web of Science ®Google Scholar
• BafadhelM, McKennaS, TerryS, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186:48–55. doi:10.1164/rccm.201108-1553OC22447964
   PubMed Web of Science ®Google Scholar
• BafadhelM, PavordID, RussellREK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5:747–759. doi:10.1016/S2213-2600(17)30217-528601554
   PubMed Web of Science ®Google Scholar